A new 3D imaging method may help doctors more accurately determine the aggressiveness of a person’s prostate cancer.
Prostate cancer is the most common cancer for men and, for men in the United States, it’s the second leading cause of death.
Some prostate cancers might be slow-growing and can be monitored over time whereas others need to be treated right away. To determine how aggressive someone’s cancer is, doctors look for abnormalities in slices of biopsied tissue on a slide. But this 2D method makes it hard to properly diagnose borderline cases.
The new non-destructive method images entire 3D biopsies instead of just a slice. In a proof-of-principle experiment, researchers imaged 300 3D biopsies taken from 50 patients—six biopsies per patient—and had a computer use 3D and 2D results to predict the likelihood that a patient had aggressive cancer. The 3D features made it easier for the computer to identify cases more likely to recur within five years.
“We show for the first time that compared to traditional pathology—where a small fraction of each biopsy is examined in 2D on microscope slides—the ability to examine 100% of a biopsy in 3D is more informative and accurate,” says senior author Jonathan Liu, professor of mechanical engineering and of bioengineering at the University of Washington.
“This is exciting because it is the first of hopefully many clinical studies that will demonstrate the value of non-destructive 3D pathology for clinical decision-making, such as determining which patients require aggressive treatments or which subsets of patients would respond best to certain drugs.”
For the study, which appears in the journal Cancer Research, researchers used prostate specimens from patients who underwent surgery more than 10 years ago, so the team knew each patient’s outcome and could use that information to train a computer to predict those outcomes. In this study, half of the samples contained a more aggressive cancer.
To create 3D samples, the researchers extracted “biopsy cores”—cylindrically shaped plugs of tissue—from surgically removed prostates and then stained the biopsy cores to mimic the typical staining used in the 2D method. Then the team imaged each entire biopsy core using an open-top light-sheet microscope, which uses a sheet of light to optically “slice” through and image a tissue sample without destroying it.
The 3D images provided more information than a 2D image—specifically, details about the complex tree-like structure of the glands throughout the tissue. These additional features increased the likelihood that the computer would correctly predict a cancer’s aggressiveness.
The researchers used new AI methods, including deep-learning image transformation techniques, to help manage and interpret the large datasets this project generated.
“Over the past decade or so, our lab has focused primarily on building optical imaging devices, including microscopes, for various clinical applications. However, we started to encounter the next big challenge toward clinical adoption: how to manage and interpret the massive datasets that we were acquiring from patient specimens,” Liu says.
“This paper represents the first study in our lab to develop a novel computational pipeline to analyze our feature-rich datasets. As we continue to refine our imaging technologies and computational analysis methods, and as we perform larger clinical studies, we hope we can help transform the field of pathology to benefit many types of patients.”
Weisi Xie, a mechanical engineering doctoral student, is the paper’s lead author. Additional coauthors are from Case Western Reserve University, the Canary Foundation, and the University of Washington.
The US Department of Defense Prostate Cancer Research Program, the National Cancer Institute; the National Heart, Lung and Blood Institute, the National Institute of Biomedical Imaging and Bioengineering, the National Institute of Mental Health, the VA Merit Review Award; the National Science Foundation, the Nancy and Buster Alvord Endowment, and the Prostate Cancer Foundation Young Investigator Award funded the work.
Jonathan Liu and University of Washington researchers Nicholas Reder, Adam Glaser, and Lawrence True are co-founders and shareholders of the spinout Lightspeed Microscopy Inc. This company has licensed the technology used in this paper.
Source: University of Washington
